U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H29N3O6
Molecular Weight 479.525
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICARDIPINE

SMILES

COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3

InChI

InChIKey=ZBBHBTPTTSWHBA-UHFFFAOYSA-N
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00622 | https://www.drugs.com/cdi/nicardipine.html | https://www.ncbi.nlm.nih.gov/pubmed/2772808 | http://reference.medscape.com/drug/cardene-iv-nicardipine-342377

Nicardipine is a potent calcium channel blockader with marked vasodilator action used to treat high blood pressure and angina. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Originator

Sources: JP 49109384

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.25 µM [IC50]
2.66 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
35.1 ng/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.1 ng/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.9 ng/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18.8 ng/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1426.2 ng × h/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2996.1 ng × h/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7510.7 ng × h/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
846.3 ng × h/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14 h
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.9 h
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20.6 h
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
NICARDIPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Other AEs: Slurred speech, Hypotension...
Other AEs:
Slurred speech
Hypotension (marked)
Bradycardia
Palpitations
Flushing
Drowsiness
Confusion
Sources: Page: p.21
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Disc. AE: Hypotension, Headache...
AEs leading to
discontinuation/dose reduction:
Hypotension
Headache
Tachycardia
Sources: Page: p.21
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Disc. AE: Rash, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Rash (0.9%)
Diarrhea (0.9%)
Tachycardia (0.9%)
Blurred vision (0.6%)
Chest pain (0.6%)
Face edema (0.6%)
Myocardial infarct (0.6%)
Vasodilatation (0.6%)
Vomiting (0.6%)
Sources: Page: p.10
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Disc. AE: Headache, Palpitation...
AEs leading to
discontinuation/dose reduction:
Headache (2.5%)
Palpitation (2.2%)
Dizziness (1.9%)
Asthenia (1.9%)
Pedal edema (1.2%)
Nausea (1.2%)
Sources: Page: p.9
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Disc. AE: Angina...
AEs leading to
discontinuation/dose reduction:
Angina
Sources: Page: p.5
AEs

AEs

AESignificanceDosePopulation
Bradycardia
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Confusion
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Drowsiness
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Flushing
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Palpitations
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Slurred speech
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Hypotension marked
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Headache Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Hypotension Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Tachycardia Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Blurred vision 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Chest pain 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Face edema 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Myocardial infarct 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vasodilatation 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vomiting 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Diarrhea 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Rash 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Tachycardia 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Nausea 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Pedal edema 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Asthenia 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Dizziness 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Palpitation 2.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Headache 2.5%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Angina Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The calcium antagonist, nicardipine, inhibits antigen-stimulated and anti-IgE-induced histamine release from basophilic leucocytes of atopic asthmatics.
1985 Aug
Effects of calcium entry blockers on blood pressure and heart rate in neurogenic hypertensive dogs.
1987
Nicardipine in the treatment of essential hypertension controlled 6-month-study comparing nicardipine with propranolol at rest and during exercise.
1987
Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
1987 Apr
[Calcium intestinal absorption in normotensive and essential hypertensive subjects before and after nicardipine].
1989 Jul
Erythromelalgia induced by nicardipine.
1989 Jul 29
Haemodynamic responses to nicardipine in humans anaesthetised with halothane.
1989 May
Erythromelalgia induced by nicardipine (inverse Raynaud's phenomenon?).
1989 May 6
Nicardipine decreases blood pressure and heart rate at nucleus tractus solitarii of spontaneously hypertensive rats.
1989 Nov
The influence of nicardipine on left ventricular hemodynamics and compliance in patients with coronary heart disease.
1990
[Hemodynamic features of hypotension induced by nicardipine in dogs].
1990 Dec
Inhibitory effects of diltiazem, verapamil, nifedipine, and nicardipine on sympathetic tachycardia in decentralized hearts of anesthetized dogs.
1990 Oct
[A nicardipine-isoflurane combination in the microsurgery of the middle ear].
1991
Heterogeneous interference of nicardipine, verapamil, and diltiazem with forearm arteriolar responsiveness to adrenergic stimulation in hypertensive patients.
1991 Jul
Nicardipine and vascular hypertrophy.
1991 Jul
Co-suppression by nicardipine, a calcium antagonist, of induction of microsomal lauric acid hydroxylation with peroxisome proliferation in clofibrate-treated rat liver.
1991 May
Adverse drug reactions leading to hospital admission.
1991 Nov-Dec
[Effects of nicardipine on the functional state of the liver in patients with ischemic heart disease].
1991 Oct
Deliberate hypotension with nicardipine or nitroprusside during total hip arthroplasty.
1991 Sep
Effects of nicardipine on the metabolic responses to food and exercise.
1992 Apr
Combined treatment with MK-801 and nicardipine reduces global ischemic damage in the gerbil.
1992 Jan
Nicardipine in the prevention of spasm-induced neurological deficits after subarachnoid hemorrhage: a dose-ranging study.
1992 Jul
Hemodynamic effects of nicardipine-induced hypotension during enflurane/nitrous oxide anesthesia in man.
1992 Oct
Profile of capsaicin-induced mouse ear oedema as neurogenic inflammatory model: comparison with arachidonic acid-induced ear oedema.
1993 Dec
Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine.
1995 Sep
Profound sinus bradycardia after intravenous nicardipine.
2002 Jul
Inactivation of aconitase during the apoptosis of mouse cerebellar granule neurons induced by a deprivation of membrane depolarization.
2003 Feb 15
Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells.
2003 Jun
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze.
2003 Mar
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells.
2003 Nov
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
2005 Aug
Exposure to a moderate intensity static magnetic field enhances the hypotensive effect of a calcium channel blocker in spontaneously hypertensive rats.
2005 Dec
Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption.
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
2005 May
Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo.
2005 Sep-Oct
Deltamethrin, a pyrethroid insecticide, is a potent inducer for the activity-dependent gene expression of brain-derived neurotrophic factor in neurons.
2006 Jan
Endogenous release of secretin from the hypothalamus.
2006 Jul
The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes.
2006 May 5
Reversible cognitive and neurological symptoms during valproic acid therapy.
2007 Apr
G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells.
2007 Apr 1
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.
2007 Jan
Nitroglycerin- and nicardipine-induced hypotension does not affect cerebral oxygen saturation and postoperative cognitive function in patients undergoing orthognathic surgery.
2008 Oct
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Comparison between atosiban and nicardipine in inducing hypotension during in-utero transfers for threatening premature delivery.
2010 Jun
Nicardipine infusion for blood pressure control in patients with subarachnoid hemorrhage.
2010 Oct
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma.
2011 Mar 1
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
2013 Dec
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Sample Use Guides

Hypertension. PO: 20-40 mg (conventional) q8hr or 30-60 mg (extended release) q12hr; IV: 5 mg/hr by slow infusion (50 mL/hr) initially; may be increased by 2.5 mg/hr every 15 minutes; not to exceed 15 mg/hr Chronic Stable Angina. 20-40 mg (conventional) PO q8h
Route of Administration: Other
The growth effects of EGF and nicardipine on U251MG cultured in serum-free and serum-supplemented (10% fetal bovine serum, FBS) medium respectively were observed by MTT colorimeritric analysis. EGF significantly enhanced the growth of U251MG cells in a dose-dependent manner in serum-free medium. The maximal effect was seen at 20 ng/ml. The effects of EGF approximated those obtained in 10% FBS. Nicardipine decreased U251MG cell proliferation, especially in serum-supplemented medium, and completely blocked the growth-stimulated effects of EGF. The combined effects of EGF (10 ng/ml) and nicardipine equaled those of nicardipine alone.
Name Type Language
NICARDIPINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
2-(BENZYLMETHYLAMINO)ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
Nicardipine [WHO-DD]
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-METHYL 5-(2-(METHYL(PHENYLMETHYL)AMINO)ETHYL) ESTER
Systematic Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, METHYL 2-(METHYL(PHENYLMETHYL)AMINO)ETHYL ESTER
Common Name English
NICARDIPINE [VANDF]
Common Name English
NICARDIPINE [MI]
Common Name English
(±)-NICARDIPINE
Common Name English
nicardipine [INN]
Common Name English
PERPIDINE
Brand Name English
NICARDIPINE (STN)
Common Name English
Classification Tree Code System Code
WHO-ATC C08CA04
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
FDA ORPHAN DRUG 712819
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
NDF-RT N0000007556
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
NCI_THESAURUS C333
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
NDF-RT N0000175421
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
WHO-VATC QC08CA04
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
NDF-RT N0000000069
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
LIVERTOX NBK548755
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C66879
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
CAS
55985-32-5
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
SMS_ID
100000091443
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
EPA CompTox
DTXSID6023363
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
MESH
D009529
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
EVMPD
SUB09225MIG
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
NDF-RT
N0000182140
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
DRUG CENTRAL
1909
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
DRUG BANK
DB00622
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
PUBCHEM
4474
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
IUPHAR
2559
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
NDF-RT
N0000187062
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY Cytochrome P450 2C8 Inhibitors [MoA]
ChEMBL
CHEMBL1484
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
MERCK INDEX
M7850
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY Merck Index
RXCUI
7396
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY RxNorm
INN
4745
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
DAILYMED
CZ5312222S
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
ECHA (EC/EINECS)
259-932-3
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
NDF-RT
N0000182141
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
LACTMED
Nicardipine
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
FDA UNII
CZ5312222S
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY
NDF-RT
N0000182137
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
WIKIPEDIA
NICARDIPINE
Created by admin on Wed Jul 05 23:14:24 UTC 2023 , Edited by admin on Wed Jul 05 23:14:24 UTC 2023
PRIMARY